Home > Dermatology > EADV 2020 > Late-Breaking News > Oral JAK 1 inhibitor leads to fast itch relieve and remarkable skin clearance in AD

Oral JAK 1 inhibitor leads to fast itch relieve and remarkable skin clearance in AD

Presented By
Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA
Conference
EADV 2020
Trial
Phase 3, Measure Up
Monotherapy with the oral Janus kinase (JAK)1 inhibitor upadacitinib showed a remarkable efficacy and speed of response in patients with moderate-to-severe atopic dermatitis (AD) in 2 replicate, multicentre, phase 3 trials [1]. The JAK inhibitor upadacitinib was specifically developed for therapy of AD because key cytokines involved in the pathogenesis of AD signal via the JAK1 pathway [2,3]. A previous phase 2b trial demonstrated that upadacitinib monotherapy was efficacious with a favourable benefit-risk profile compared with placebo in adults with moderate-to-severe AD. The 2 replicate, randomised, double-blind, phase 3 trials Measure Up 1 (NCT03569293) and Measure Up 2 (NCT03607422) aimed to evaluate the efficacy and safety of monotherapy with upad...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on